A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT04928846 · readout ≤ 864 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
768estimated
Sites
317
Countries
Argentina, Australia, Austria +29
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-25 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2021-06-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Cancer
Interventions
- Biological: Telisotuzumab Vedotin — also filed as ABBV-399
- Drug: Docetaxel
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS) per Blinded Independent Central Review (BICR)
measured Up to approximately 39 months
Overall Survival (OS)
measured Up to approximately 39 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed